Blood Products

  • William D. Hoffman

Abstract

Although progress has been made in ensuring the safety of transfusions, clinicians restrict the use of blood products to avoid exposing patients to allogeneic risk and conserve the supply (1). The potential alternatives, benefits, and risks associated with each transfusion are assessed before administration and, when possible, discussed with the patient. Table 1 shows the commonly administered blood components.

Keywords

Blood Product Fresh Freeze Plasma Graft Versus Host Disease Platelet Transfusion Recombinant Human Erythropoietin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999; 340: 438–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-frozen plasma, cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994; 271: 777–81.CrossRefGoogle Scholar
  3. 3.
    Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU: Is there a reason? Chest 1995; 108: 767–71.Google Scholar
  4. 4.
    Greenburg AG. A physiologic basis for red blood cell transfusion decisions. Am J Surg 1995; 170 (6A Suppl): 44S - 48S.PubMedCrossRefGoogle Scholar
  5. 5.
    Hsia CC. Respiratory function of hemoglobin. N Engl J Med 1998; 338: 239–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Stehling L, Simon TL. The red blood cell transfusion trigger. Physiology and clinical studies. Arch Pathol Lab Med 1994; 118: 429–34.PubMedGoogle Scholar
  8. 8.
    Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 393–402.PubMedGoogle Scholar
  9. 9.
    Simon TL, Alverson DC, AuBuchon J, Cooper ES, DeChristopher PJ, Glenn GC, Gould SA, Harrison CR, Milam JD, Moise KJ Jr, Rodwig FR Jr, Sherman LA, Shulman IA, Stehling L. Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 1998; 122: 130–8.PubMedGoogle Scholar
  10. 10.
    Weiskopf RB, Viele MK, Feiner J, Kelley S, Lieberman J, Noorani M, Leung JM, Fisher DM, Murray WR, Toy P, Moore MA. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279: 217–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Mathru M, Kleinman B, Blakeman B, Sullivan H, Kumar P, Dries DJ. Myocardial metabolism and adaptation during extreme hemodilution in humans after coronary revascularization. Crit Care Med 1992; 20: 1420–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Hebert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B, Blajchman M, Schweitzer I, Pagliarello G. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1997; 155: 1618–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409–17.Google Scholar
  14. 14.
    Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998; 44: 361–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, Vincent JL. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Rutherford CJ, Schneider TJ, Dempsey H, Kirn DH, Brugnara C, Goldberg MA. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med 1994; 96: 13945.CrossRefGoogle Scholar
  18. 18.
    Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989; 4: 883–7.PubMedGoogle Scholar
  19. 19.
    Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655–63.PubMedGoogle Scholar
  20. 20.
    Muench KH. Hemochromatosis and infection: alcohol and iron, oysters and sepsis. Am J Med 1989; 87: 40N - 43N.PubMedGoogle Scholar
  21. 21.
    Oppenheimer SJ. Iron and infection: the clinical evidence. Acta Paediatr Scand Suppl 1989; 361: 53–62.PubMedGoogle Scholar
  22. 22.
    Sarraf-Yazdi S, Sheng H, Grocott HP, Bart RD, Pearlstein RD, Steffen RP, Warner DS. Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat. Brain Res 1999; 826: 172–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Sprung J, Mackenzie CF, Bamas GM, Williams JE, Parr M, Christenson RH, Hoff BH, Sakamoto R, Kramer A, Lottes M. Oxygen transport and cardiovascular effects of resuscitation from severe hemorrhagic shock using hemoglobin solutions. Crit Care Med 1995; 23: 1540–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Newman BH, Shafer AW, Saeed SM. Patterns of use of group O, Rh-negative red cells in a large metropolitan area and an action plan to control utilization. Transfusion 1996; 36: 209–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. JAMA 1995; 274: 1374–9.CrossRefGoogle Scholar
  26. 26.
    Klein HG. Immunomodulatory aspects of transfusion: a once and future risk? Anesthesiology 1999; 91: 861–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Francis DM. Relationship between blood transfusion and tumour behaviour. Br J Surg 1991; 78: 1420–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Ownby HE, Kong F, Watanabe K, Tu Y, Nass CC. Analysis of donor return behavior. Retrovirus Epidemiology Donor Study. Transfusion 1999; 39: 1128–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Silberman S. Platelets: preparations, transfusion, modifications, and substitutes. Arch Pathol Lab Med 1999; 123: 889–94.PubMedGoogle Scholar
  30. 30.
    Neff PE, Kelly KP, Tobias JD. Septic shock from the administration of a bacterially contaminated platelet transfusion. South Med J 1999; 92: 1194–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Chiu EK, Yuen KY, Lie AK, Liang R, Lau YL, Lee AC, Kwong YL, Wong S, Ng MH, Chan TK. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994; 34: 950–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Cuff Opin Hematol 1999; 6: 437–41.CrossRefGoogle Scholar
  33. 33.
    Koyanagi T, Kyo S, Hirooka E, Koyama I, Omoto R. Redo without transfusion in a patient with idiopathic thrombocytopenic purpura. Ann Thorac Surg 2000; 69: 1261–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Engelfriet CP, Reesink HW, Blajchman MA, Muylle L, Kjeldsen-Kragh J, Kekomaki R, Yomtovian R, Hocker P, Stiegler G, Klein HG, Soldan K, Barbara J, Slopecki A, Robinson A, Seyfried H. Bacterial contamination of blood components. Vox Sang 2000; 78: 59–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council. S Afr Med J 1998; 88: 1344–7.Google Scholar
  36. 36.
    Humphries JE. Transfusion therapy in acquired coagulopathies. Hematol Oncol Clin North Am 1994; 8: 1181–201.PubMedGoogle Scholar
  37. 37.
    Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modem therapy. Blood Rev 1993; 7: 94–103.PubMedCrossRefGoogle Scholar
  38. 38.
    Klein HG, Dodd RY, Dzik WH, Luban NL, Ness PM, Pisciotto P, Schiff PD, Snyder EL. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38: 102–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Williams EF. Current transfusion therapy: indications for basic components. Clin Lab Sci 1994; 7: 219–24.PubMedGoogle Scholar
  40. 40.
    Adkins D, Ali S, Despotis G, Dynis M, Goodnough LT. Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte-colony-stimulating factor. Transfusion 1998; 38: 557–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Rieger A, Philippi W, Spies C, Eyrich K. Safe and normothermic massive transfusions by modification of an infusion warming and pressure device. J Trauma 1995; 39: 686–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Cinat ME, Wallace WC, Nastanski F, West J, Sloan S, Ocariz J, Wilson SE. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 1999; 134: 964–70.PubMedCrossRefGoogle Scholar
  43. 43.
    Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life- threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997; 42: 857–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Jeter EK, Spivey MA. Noninfectious complications of blood transfusion. Hematol Oncol Clin North Am 1995; 9: 187–204.PubMedGoogle Scholar
  45. 45.
    Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992; 32: 601–6.PubMedCrossRefGoogle Scholar
  46. 46.
    von Zabern I, Ehlers M, Grunwald U, Mauermann K, Greinacher A. Release of mediators of systemic inflammatory response syndrome in the course of a severe delayed hemolytic transfusion reaction caused by anti-D. Transfusion 1998; 38: 459–68.Google Scholar
  47. 47.
    Gorman TE, Julius CJ, Barth RF, Ng A, Kennedy MS, Prior TW, Allen J, Lasky LC. Transfusion- associated graft-vs-host disease. A fatal case caused by blood from an unrelated HLA homozygous donor. Am J Clin Pathol 2000; 113: 732–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Ramsey G. The pathophysiology and organ-specific consequences of severe transfusion reactions. New Horiz 1994; 2: 575–81.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • William D. Hoffman
    • 1
  1. 1.Massachusetts General HospitalBostonUSA

Personalised recommendations